Reported 3 days ago
Recursion Pharmaceuticals experienced a 24% drop in stock value this week, following disappointing first-quarter earnings and an announcement to cut a significant portion of its development pipeline. Issues surrounding President Trump's planned research cuts, which many biotech leaders believe will hinder capital raising, added to the company's challenges. Despite its promising use of AI, investors are cautioned due to ongoing losses and uncertainty in future funding.
Source: YAHOO